医渡科技 7 通讯｜2025 年

Yidu Tech Events in July 2025

集团亮点

Business Update

医渡科技宫如璟受邀出席 WAIC 2025 大会

Yidu Tech's Gong Rujing Invited to Attend WAIC 2025

7 月 28 日，医渡科技创始人、董事长宫如璟作为 AI 医疗领域杰出代表受邀出席 2025 世界人工智能大会 "AI 向善" 论坛，通过主旨演讲和圆桌分享系统阐释了医渡践行 "AI 向善" 的落地路径：以技术突破资源壁垒，用科技温暖生命。宫如璟认为，医疗 AI 的最终价值是服务于人、温暖生命。而要实现这些价值，不仅需要有对生命复杂度的敬畏，机构间的信任与合作，更需要坚守以人为本的初心。

On July 28, Gong Rujing, Founder and Chairwoman of Yidu Tech, was invited to attend the 2025 World Artificial Intelligence Conference "AI for Good" forum as an outstanding representative in the field of AI healthcare. Through a keynote speech and panel discussion, she systematically elaborated on Yidu Tech's implementation path of "AI for Good": breaking resource barriers with technological breakthroughs and warming lives with technology. Gong Rujing believes that the ultimate value of AI medical is to serve people and bring warmth to life. To realize these values, it not only requires deep respect for the complexity of life and trust and cooperation among institutions, but also the steadfast adherence to a people-centered original aspiration.

医渡科技深度赋能国家哮喘诊疗重大专项正式启动

National Asthma Diagnosis and Treatment Project Empowered by Yidu Tech Officially Launched

"癌症、心脑血管、呼吸和代谢性疾病防治研究"国家科技重大专项"哮喘诊疗管理新体系构建：从易感人群识别、早诊到基于多维度表型的精准干预研究"项目启动会在南昌举办。该项目由浙江大学医学院附属第二医院呼吸与危重症医学科主任李雯教授牵头，医渡科技与中日友好医院、上海交通大学附属瑞金医院等多家医疗机构协同攻关，旨在构建哮喘诊疗管理新体系，打造一个具有原创性的"中国方案"，提升哮喘患者的生活质量和健康水平。

The kick-off meeting for the national major science and technology project "Research on Prevention and Treatment of Cancer, Cardiovascular, Respiratory and Metabolic Diseases" — specifically the subproject titled "Establishing a New System for Asthma Diagnosis and Management: From Identifying Susceptible Populations and Early Diagnosis to Precision Interventions Based on Multidimensional Phenotypes" — was

held in Nanchang. Led by Professor Li Wen, Director of the Department of Pulmonary and Critical Care Medicine at the Second Affiliated Hospital Zhejiang University School of Medicine, the project brings together Yidu Tech, China-Japan Friendship Hospital, Ruijin Hospital Affiliated to Shanghai JiaoTong University School of Medicine, and other medical institutions. It aims to develop an innovative asthma diagnosis and treatment management system, creating an original "China Solution" to improve the quality of life and health outcomes of asthma patients.

医渡科技加入可信数据空间发展联盟，推动数据要素价值释放与创新应用

Yidu Tech Joins Trusted Data Spaces Alliance to Drive Data Value & Innovation

医渡科技正式成为可信数据空间发展联盟成员单位，该联盟由国家数据局指导，于 2025 年 4 月 29 日在第八届数字中国建设峰会宣告成立，汇聚了众多央企、研究院所和龙头企业，致力于打造可信数据空间标杆，构建协同创新生态。作为联盟在 AI 医疗领域的核心成员，医渡科技将凭借其在医疗人工智能与大数据技术领域的丰富实践和沉淀，依

托联盟平台，通过数据整合、算力赋能、场景落地及生态共建，积极助力全面释放数据要素价值。

Yidu Tech has officially become a member of the Trusted Data Spaces Alliance. Guided by the National Data Administration, the Alliance was launched on April 29, 2025, during the 8th Digital China Summit. It brings together numerous central enterprises, research institutes, and leading companies, aiming to establish benchmark models for trusted data spaces and foster a collaborative innovation ecosystem. As a core member in the field of AI healthcare, Yidu Tech will leverage its extensive experience in AI medical and big data technologies. Through the Alliance platform, the company will promote the full realization of data value by integrating data assets, empowering with computing capabilities, implementing application scenarios, and fostering collaborative ecosystems.

医渡科技亮相 2025 T20+大会，共探 AI 如何重塑研发效率边界

Yidu Tech Showcases at 2025 T20+ Conference, Exploring How AI Redefines R&D Efficiency Boundaries

医渡科技携智能临床研究一体化解决方案亮相苏州同写意"T20+大会"，系统呈现了 AI 驱动临床研究效率提升的可复制路径。该解决方案在临床试验方案优化、患者智能招募、临床运营等药物研发关键环节大幅提速超 30%，有效推动了研发效率提升、产品上市路径优化及创新成本降低。

At the T20+ Conference hosted by Tonacea in Suzhou, Yidu Tech presented its intelligent end-to-end clinical research solution, offering a systematic and replicable pathway for enhancing clinical research efficiency through AI. The solution accelerates key phases of drug development — including protocol design optimization, intelligent patient recruitment, and clinical operations — by over 30%, effectively boosting R&D efficiency, streamlining product launch timelines, and reducing innovation costs.

医渡科技出席民营医院智慧管理发展研讨会，以 AI 助力新药立项提质增效

Yidu Tech Attends Private Hospital Smart Management Development Forum

在上海召开的"民营医院智慧管理发展研讨会"上，医渡科技高级解决方案总监章勇以"大数据管控平台的建设实践与探索"为题发表演讲。此次研讨会汇聚多家头部民营医院管理者与智慧化建设领域专家，核心议题直指医院数智化转型的"深水区突破"。章勇在演讲中不仅系统拆解了基于大模型赋能的数据中心建设方案，更以可落地、可复制的实践路径，为民营医院从"要转型"到"会转型"提供了关键解法。

At the "Private Hospital Smart Management Development Forum" held in Shanghai, Zhang Yong, Senior Solutions Director at Yidu Tech, delivered a keynote speech titled "Construction Practice and Exploration of Big Data Governance Platforms." The forum brought together leaders from top-tier private hospitals and experts in smart healthcare development, focusing on breaking through the 'deep-water zone' of hospital digital-intelligent transformation. In his speech, Zhang Yong not only systematically deconstructed a big model-empowered data center solution, but also provided actionable and replicable implementation pathways—delivering key solutions to help private hospitals move from simply wanting transformation to effectively achieving it.

业务进展

Business Progress

医渡科技连续三年主运营，2025 年度深圳惠民保参保超 615 万

Yidu Tech Serves as Main Operator for Shenzhen Supplementary Insurance for Three Consecutive Years, Over 6.15 Million Insured in 2025

医渡科技连续三年担任主运营平台的 2025 年度"深圳惠民保"收官，参保人数超 615 万再创历史新高，其中超 11 万名异地医保的深圳户籍人员首次纳入参保，另有近 2.6 万家企业为超 105 万名职工参保，三年累计参保人次超 1800 万；公司依托"AI 医疗大脑" YiduCore 提供全流程服务，已深度参与 5 省 12 市"惠民保"项目，服务超 4000 万人次，彰显了在千万人口级城市的综合运营与科技赋能实力，为构建多层次医疗保障体系持续贡献力量。

Yidu Tech has successfully concluded its third consecutive year as the main operating platform for the 2025 "Shenzhen Supplementary Insurance" program, achieving a record-breaking participation of over 6.15 million insured residents. This includes more than 110,000 Shenzhen-registered residents with out-of-town medical insurance joining for the first time, and nearly 26,000 enterprises insuring over 1.05 million employees. Over the past three years, cumulative enrollment has exceeded 18 million person-times. Leveraging its AI medical brain, YiduCore, the company provided full-process services and has been deeply involved in "Supplementary Insurance" projects across 12 cities in 5 provinces, serving over 40 million person-times. This demonstrates Yidu Tech's comprehensive operational capabilities and technological empowerment in megacities, and its continued contribution to building a multi-tiered healthcare security system.

医渡科技全程助力杰科生物雷珠单抗生物类似药申报上市

Yidu Tech Fully Supports JECHO Ranibizumab Biosimilar Marketing Application

杰科生物申报的雷珠单抗注射液（研发代码：JL14002）上市许可申请获国家药品监督管理局（NMPA）受理。作为药品 III 期临床试验的核心服务伙伴，医渡科技提供的招募、运营、SMO 三位一体临床研究服务，为试验的顺利推进和高效完成给予了强有力的保障，也为此次上市许可申请的成功受理奠定了坚实基础。

The marketing authorization application for ranibizumab injection (development code: JL14002) submitted by JECHO has been accepted by the National Medical Products Administration (NMPA). As a core service partner for the product's Phase III clinical trial, Yidu Tech provided an integrated suite of clinical research services — covering patient recruitment, trial operations, and site management organization (SMO). These services offered strong support for the smooth progress and efficient completion of the trial, laying a solid foundation for the successful acceptance of this marketing authorization application.

医渡科技中标某知名跨国药企多个项目

Yidu Tech Wins Multiple Project Bids from a Leading Multinational Pharmaceutical Company

医渡科技连中某跨国药企多个实体肿瘤真实世界研究项目。系列项目中标不仅体现了客户对医渡科技专业能力与解决方案的高度认可和持续信任，更彰显了双方战略合作的深度与广度，进一步巩固了医渡科技在真实世界证据生成和上市后研究领域的优势地位。

Yidu Tech has won multiple real-world study projects on solid tumors from a multinational pharmaceutical company. These project awards not only reflect the client's strong recognition of and continued trust in Yidu Tech's professional capabilities and solutions, but also highlight the depth and breadth of the strategic collaboration between the two parties, further consolidating Yidu Tech's leading position in real-world evidence generation and post-marketing research.

医渡科技中标某 MNC 某罕见病上市后承诺性研究项目

Yidu Tech Wins Bid for a Post-Marketing Commitment Study Project on a Rare Disease from a Multinational Corporation

医渡科技中标某 MNC 某罕见病上市后承诺性研究项目，该项目有望成为运用真实世界数据支持监管决策的典范案例。项目创新性地采用回顾性与前瞻性相结合的研究方法，成功整合博鳌乐城先行区真实世界数据与内地诊疗数据，标志着公司在创新研究模式与真实世界证据应用领域取得进一步突破，具有里程碑意义。

Yidu Tech has won the bid for a post-marketing commitment study project on a rare disease from a multinational corporation, a project poised to become a benchmark case for using real-world evidence to support regulatory decision-making. The study adopts an innovative approach that combines retrospective and prospective methodologies, successfully integrating real-world evidence from the Boao Lecheng International Medical Tourism Pilot Zone with diagnosis and treatment data from mainland China. This marks a further breakthrough for the company in innovative

research models and the application of real-world evidence, carrying significant milestone value.

集团荣誉

**Honors of Yidu Tech**

医渡科技荣膺毕马威健康科技 50 强

Yidu Tech Honored in KPMG's Top 50 Health Tech Companies

医渡科技凭借在 AI 医疗领域的长期深耕，以及大模型技术与医疗场景深度融合的卓越成效，成功入选毕马威中国首届健康科技 50 榜单。该评选围绕企业战略定位、商业运营模式、人力资源架构等七大核心维度展开，底层逻辑聚焦于以科技赋能"新三医联动"。医渡科技在医疗、医药、医保科技三大领域的业务布局与评选框架高度契合，其以"数据 + AI"双轮驱动打通"三医联动"的创新实践获得充分认可。此次入选不仅印证了公司在技术与战略整合层面的示范价值，更彰显了行业地位；未来，医渡科技将持续夯实技术基座，为行业发展注入更强动能。

Yidu Tech has been named to KPMG China's inaugural "HealthTech 50" list, in recognition of its long-term dedication to AI-powered healthcare and outstanding achievements in integrating large language model technologies with medical scenarios. The evaluation spanned seven core dimensions—including corporate strategic positioning, business operations model, and human resources structure—underpinned by the logic of empowering the "New Three Medical Linkages" through technology. Yidu Tech's business layout across healthcare, pharmaceuticals, and medical insurance technology aligns closely with the evaluation framework, and its innovative practice of connecting the "Three Medical Linkages" through a dual engine of "Data +

AI" has received full recognition. This inclusion not only affirms the company's exemplary value in integrating technology and strategy but also highlights its strong industry standing. Looking ahead, Yidu Tech will continue to strengthen its technological foundation and inject greater momentum into the industry's development.

医渡科技 AI 中台项目获评"北京市人工智能赋能行业发展典型案例"

Yidu Tech's AI Middleware Platform Honored as a "Beijing AI-Enabled Industry Development Model Case"

医渡科技作为中国 AI 医疗变革驱动者，亮相近日在北京举行的 2025 全球数字经济大会。该大会由北京市人民政府、国家互联网信息办公室、国家数据局、新华通讯社、联合国开发计划署主办。会上，医渡科技"基于 AI 中台及国产大模型技术在肿瘤专科诊疗领域的应用"创新案例成功入选"北京市人工智能赋能行业发展典型案例（2025）"，

这一荣誉高度肯定了其在推动人工智能与医疗行业深度融合、解决行业关键痛点方面的突出贡献。

As a driving force in China's AI-powered healthcare transformation, Yidu Tech recently showcased its innovations at the Global Digital Economy Conference 2025 held in Beijing. The event was co-hosted by the People's Government of Beijing Municipality, the Cyberspace Administration of China, the National Data Administration, Xinhua News Agency, and the United Nations Development Programme. At the conference, Yidu Tech's innovative case — "Application of AI Middleware Platform and Domestic Large Language Model Technology in Oncology Specialty Diagnosis and Treatment" — was selected as a 2025 Beijing AI-Enabled Industry Development Model Case. This honor is a strong recognition of the company's outstanding contribution to promoting deep integration of AI and the healthcare industry and addressing critical industry challenges.

医渡科技 AI 中台获评"AI Solutions for SME 全球案例"

Yidu Tech's AI Middleware Platform Honored as a "Global AI Solutions for SME Case"

在 2025 世界人工智能大会上，医渡科技 AI 中台实践获评"AI Solutions for SME 全球案例"，这不仅是对其技术实力与实践价值的高度认可，更是其以实际行动参与全球健康治理的生动注脚。

At the 2025 World Artificial Intelligence Conference, Yidu Tech's AI middleware platform was recognized as a "Global AI Solutions for SME" case. This honor is not only a strong acknowledgment of its technological capabilities and practical value, but also a testament to the company's active contribution to global health governance through concrete actions.

投资者交流

Investor Communication

医渡科技 IRD 出席两场策略会，深度沟通医疗 AI 核心优势

Yidu Tech IRD Attends Two Strategy Conferences, Deeply Communicates Core Strengths in AI Medical

医渡科技投资者关系总监 Helena Wang 受邀出席长江证券"蓝海算赋，智启万物——AI 产业链精品闭门交流会"与国盛证券"创新启航 王者时刻——第 20 届医药百家上市公司交流会"。系列活动中，与公私募基金、保险资管等机构专业投资者深度互动，围绕公司在医疗人工智能领域技术创新路径、业务推进节奏、未来战略布局等展开交流，传递医渡科技在 AI 医疗赛道构建的核心竞争力与增长潜力。通过详实分享技术落地成果、商业化探索进程，强化资本市场对公司价值认知，持续拓宽与投资者互动深度，为长期发展凝聚市场信心。

Yidu Tech's IRD Helena Wang was invited to attend the Changjiang Securities "AI Industry Chain Premium Closed-door Roundtable" and the Guosheng Securities "20th Annual Top 100 Listed Healthcare Companies Conference." During these events, she engaged in in-depth discussions with institutional investors, including public and private funds, insurance asset management, and other professionals. The conversations focused on the company's technological innovation roadmap in AI medical, business development pace, and future strategic layout—conveying Yidu Tech's core competitiveness and growth potential in the AI healthcare sector. By sharing detailed achievements in technology implementation and progress in commercialization, Yidu Tech reinforced capital market recognition of its value, deepened investor engagement, and strengthened market confidence in its long-term development.